MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform
Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD ($30.5 million CAD) for year ended December 31, 2020 NEW YORK, March 30, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its annual 2020 financial results for the year ended December 31, 2020. […]
Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development
Toronto, Ontario–(Newsfile Corp. – March 30, 2021) – Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF)(“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appointment of Dr. Malik […]
